<DOC>
	<DOCNO>NCT00789724</DOCNO>
	<brief_summary>Thousands patient die daily early late complication heart attack ( acute myocardial infarction , AMI ) . Patients survive AMI remain high risk death adverse cardiac remodeling ( dysfunction enlargement heart ) lead heart failure ( weaken heart ) . Current intervention proven reduce adverse remodel progression heart failure include early reperfusion ( restore blood flow heart muscle ) long-term use medicine block effect hormone ( angiotensin II , norepinephrine aldosterone ) involve adverse remodeling . Despite treatment , however , many patient continue develop heart failure within 1 year AMI . These patient high risk death . Numerous change occur heart patient AMI lead adverse remodeling . Ischemia ( lack oxygen ) infarction ( cell damage ) lead increase interleukin-1 ( IL-1 ) production heart . IL-1 play critical role adverse cardiac remodel coordinate inflammatory pathway ( lead wound heal ) apoptotic pathway ( lead cell death ) . In opposition IL-1 activity , human body produce natural IL-1 receptor antagonist block effect IL-1 . The drug form IL-1 receptor antagonist ( anakinra ) currently FDA approve treatment rheumatoid arthritis , inflammatory disease characterize excessive IL-1 activity . Experimental study show anakinra able prevent cardiac remodel improve survival mouse AMI . We hypothesize anakinra show similar benefit human patient prevent adverse remodel heart failure AMI .</brief_summary>
	<brief_title>Anakinra Prevent Post-infarction Remodeling</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>Age &gt; 18 year Acute ( &lt; 24 hour ) onset chest pain New presumably new ST elevation ECG Planned coronary angiography percutaneous revascularization Inability give inform consent Late presentation ( &gt; 24 hour ) Unsuccessful revascularization urgent coronary bypass surgery Hemodynamic instability Endstage congestive heart failure ( AHA/ACC stage C/D , NYHA class IV ) Preexisting severe LV dysfunction ( LVEF &lt; 20 % ) severe valvular disease Severe asthma Pregnancy ( preenrollment pregnancy test ) Contraindications cardiac MRI cardiac angiography Severe coagulopathy ( INR &gt; 2.0 , Platelet count &lt; 50,000/mm3 ) Severe renal insufficiency ( creatinine clearance &lt; 30 ml/min/m2 ) Recent ( &lt; 14 day ) use antiinflammatory drug ( NSAIDS exclude ) Chronic inflammatory disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>acute myocardial infarction</keyword>
</DOC>